Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Active not recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neurotoxicity Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Cytokine Release Syndrome 1

Interventions

pembrolizumab 247Nivolumab 144Cyclophosphamide 137Cisplatin 137Paclitaxel 115Carboplatin 111Gemcitabine 100Radiotherapy 86Dexamethasone 84Docetaxel 79Ipilimumab 70atezolizumab 68Doxorubicin 63Fluorouracil 60Blood Specimen Collection 60Bevacizumab 59Etoposide 55fludarabine 54Rituximab 54Oxaliplatin 52Prednisone 51Lenalidomide 51Surveys and Questionnaires 50Cetuximab 47Standard of Care 46Capecitabine 46Radiosurgery 44Magnetic Resonance Spectroscopy 44lenvatinib 43durvalumab 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Interleukin 1 Receptor Antagonist Protein × 1 year × Clear all
NCT02021422 2026-02-18

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Baylor Research Institute

Phase 1 Completed
13 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Massachusetts General Hospital

Phase 2 Completed
15 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

NCT04359784 2025-10-23

Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

Fred Hutchinson Cancer Center

Phase 2 Completed
27 enrolled 15 charts
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡